Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and features following CAR-T treatment failure. Of 305 adults who received CD19-CAR-T, 182 experienced disease recurrence or progression (1-year cumulative incidence 63% [95%CI: 57-69]). Of 52 post-CAR-T biopsies evaluated by flow cytometry, 49 (94%) expressed CD19. Subsequent anti-cancer treatment was administered in 135/182 (74%) patients with CAR-T treatment failure. Median OS from the first post-CAR-T treatment was 8 months (95%CI 5.6-11.0). Polatuzumab-, standard chemotherapy-, and lenalidomide-based treatments were the most common approaches after CAR-T. No complete responses (CRs) were observed with conventional chemotherapy, while CR rates exceeding 30% were seen following polatuzumab- or lenalidomide-based therapies. Factors associated with poor OS among patients treated post-CAR-T were pre-CAR-T bulky disease (HR 2.27 [1.10-4.72]), lack of response to CAR-T (2.33 [1.02-5.29]), age >65 years (HR 2.65 [1.49-4.73]) and elevated LDH at post-CAR-T treatment (HR 2.95 [1.61-5.38]). The presence of ≥2 of these factors was associated with inferior OS compared to ≤1 (56% vs. 19%). In this largest analysis to date of patients who progressed or relapsed after CD19-CAR-T, survival is poor, though novel agents such as polatuzumab and lenalidomide may have hold promise.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Leukemia - 37(2023), 1 vom: 05. Jan., Seite 154-163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alarcon Tomas, Ana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD19 |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 03.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-022-01739-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34849131X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34849131X | ||
| 003 | DE-627 | ||
| 005 | 20231226040349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-022-01739-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM34849131X | ||
| 035 | |a (NLM)36335261 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alarcon Tomas, Ana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 03.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and features following CAR-T treatment failure. Of 305 adults who received CD19-CAR-T, 182 experienced disease recurrence or progression (1-year cumulative incidence 63% [95%CI: 57-69]). Of 52 post-CAR-T biopsies evaluated by flow cytometry, 49 (94%) expressed CD19. Subsequent anti-cancer treatment was administered in 135/182 (74%) patients with CAR-T treatment failure. Median OS from the first post-CAR-T treatment was 8 months (95%CI 5.6-11.0). Polatuzumab-, standard chemotherapy-, and lenalidomide-based treatments were the most common approaches after CAR-T. No complete responses (CRs) were observed with conventional chemotherapy, while CR rates exceeding 30% were seen following polatuzumab- or lenalidomide-based therapies. Factors associated with poor OS among patients treated post-CAR-T were pre-CAR-T bulky disease (HR 2.27 [1.10-4.72]), lack of response to CAR-T (2.33 [1.02-5.29]), age >65 years (HR 2.65 [1.49-4.73]) and elevated LDH at post-CAR-T treatment (HR 2.95 [1.61-5.38]). The presence of ≥2 of these factors was associated with inferior OS compared to ≤1 (56% vs. 19%). In this largest analysis to date of patients who progressed or relapsed after CD19-CAR-T, survival is poor, though novel agents such as polatuzumab and lenalidomide may have hold promise | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 700 | 1 | |a Fein, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Fried, Shalev |e verfasserin |4 aut | |
| 700 | 1 | |a Flynn, Jessica R |e verfasserin |4 aut | |
| 700 | 1 | |a Devlin, Sean M |e verfasserin |4 aut | |
| 700 | 1 | |a Fingrut, Warren B |e verfasserin |4 aut | |
| 700 | 1 | |a Anagnostou, Theodora |e verfasserin |4 aut | |
| 700 | 1 | |a Alperovich, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nishi |e verfasserin |4 aut | |
| 700 | 1 | |a Fraint, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Scordo, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Batlevi, Connie Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Besser, Michal J |e verfasserin |4 aut | |
| 700 | 1 | |a Dahi, Parastoo B |e verfasserin |4 aut | |
| 700 | 1 | |a Danylesko, Ivetta |e verfasserin |4 aut | |
| 700 | 1 | |a Giralt, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Imber, Brandon S |e verfasserin |4 aut | |
| 700 | 1 | |a Jacoby, Elad |e verfasserin |4 aut | |
| 700 | 1 | |a Kedmi, Meirav |e verfasserin |4 aut | |
| 700 | 1 | |a Nagler, Arnon |e verfasserin |4 aut | |
| 700 | 1 | |a Palomba, M Lia |e verfasserin |4 aut | |
| 700 | 1 | |a Roshal, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Salles, Gilles A |e verfasserin |4 aut | |
| 700 | 1 | |a Sauter, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Shem-Tov, Noga |e verfasserin |4 aut | |
| 700 | 1 | |a Shimoni, Avichai |e verfasserin |4 aut | |
| 700 | 1 | |a Yahalom, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Yerushalmi, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Gunjan L |e verfasserin |4 aut | |
| 700 | 1 | |a Avigdor, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Perales, Miguel-Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Shouval, Roni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 37(2023), 1 vom: 05. Jan., Seite 154-163 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:1 |g day:05 |g month:01 |g pages:154-163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-022-01739-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 1 |b 05 |c 01 |h 154-163 | ||